<html>
<head>
    <title>report_cmo-122115.htm</title>
    <!--Licensed to: Acorda-->
    <!--Document Created using EDGARizer 2020 5.5.0.0-->
    <!--Copyright 1995 - 2014 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 20.5pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman, serif; FONT-WEIGHT: bold; DISPLAY: inline">UNITED STATES</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 20.5pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman, serif; FONT-WEIGHT: bold; DISPLAY: inline">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif; FONT-WEIGHT: bold; DISPLAY: inline">WASHINGTON, D.C. 20549</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 20.5pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman, serif; FONT-WEIGHT: bold; DISPLAY: inline">FORM&#160;8-K</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 13.7pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif; FONT-WEIGHT: bold; DISPLAY: inline">CURRENT REPORT</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 13.7pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif; FONT-WEIGHT: bold; DISPLAY: inline">Pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 13.7pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline"><font style="FONT-SIZE: 10pt; DISPLAY: inline">Date of Report (Date of Earliest Event Reported):&#160; </font><font style="FONT-WEIGHT: bold; DISPLAY: inline">December 21, 2015</font></font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 20.5pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman, serif; FONT-WEIGHT: bold; DISPLAY: inline">Acorda Therapeutics,&#160;Inc.</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">(Exact name of registrant as specified in its charter)</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="">
<tr>
<td valign="top" width="27%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman, serif; FONT-WEIGHT: bold; DISPLAY: inline">Delaware</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td valign="top" width="27%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman, serif; FONT-WEIGHT: bold; DISPLAY: inline">000-50513</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td valign="top" width="27%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman, serif; FONT-WEIGHT: bold; DISPLAY: inline">13-3831168</font></div>
</td>
</tr><tr>
<td valign="top" width="27%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman, serif; DISPLAY: inline">(State or other jurisdiction</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td valign="top" width="27%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman, serif; DISPLAY: inline">(Commission</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td valign="top" width="27%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman, serif; DISPLAY: inline">(I.R.S. Employer</font></div>
</td>
</tr><tr>
<td valign="top" width="27%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman, serif; DISPLAY: inline">of incorporation)</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td valign="top" width="27%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman, serif; DISPLAY: inline">File Number)</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td valign="top" width="27%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman, serif; DISPLAY: inline">Identification No.)</font></div>
</td>
</tr><tr>
<td valign="top" width="27%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td align="left" valign="bottom" width="2%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td valign="top" width="27%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td align="left" valign="bottom" width="2%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td valign="top" width="27%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
</tr><tr>
<td valign="middle" width="27%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td valign="top" width="2%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td valign="top" width="27%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman, serif; FONT-WEIGHT: bold; DISPLAY: inline">420 Saw Mill River Road,</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman, serif; FONT-WEIGHT: bold; DISPLAY: inline">Ardsley, NY</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td valign="top" width="27%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman, serif; FONT-WEIGHT: bold; DISPLAY: inline">10502</font></div>
</td>
</tr><tr>
<td valign="middle" width="27%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td valign="top" width="2%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td valign="top" width="27%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman, serif; DISPLAY: inline">(Address of principal executive offices)</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td valign="top" width="27%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman, serif; DISPLAY: inline">(Zip Code)</font></div>
</td>
</tr><tr>
<td valign="top" width="27%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td align="left" valign="bottom" width="2%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td valign="top" width="27%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td align="left" valign="bottom" width="2%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td valign="top" width="27%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
</tr><tr>
<td colspan="5" valign="top" width="84%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman, serif; DISPLAY: inline">Registrant&#8217;s telephone number, including area code:&#160;&#160;<font style="FONT-WEIGHT: bold; DISPLAY: inline">(914) 347-4300</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; LINE-HEIGHT: 13.7pt; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif; FONT-WEIGHT: bold; DISPLAY: inline">Not Applicable</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">Former name or former address, if changed since last report</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">&#160;Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline"><font style="DISPLAY: inline" face="Wingdings">o</font>&#160;Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline"><font style="DISPLAY: inline" face="Wingdings">o</font>&#160;Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline"><font style="DISPLAY: inline" face="Wingdings">o</font>&#160;Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline"><font style="DISPLAY: inline" face="Wingdings">o</font>&#160;Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">&#160;</font></div>

<div style="DISPLAY: block; LINE-HEIGHT: 13.7pt; TEXT-INDENT: 0pt"><br>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>
</div>
</div>

<br>
<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="">
<tr valign="top" style="LINE-HEIGHT: 12.55pt;">
<td style="WIDTH: 72pt">
<div style="MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"><font style="FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif; FONT-WEIGHT: bold; DISPLAY: inline">Item 5.02</font></div>
</td>
<td>
<div align="left"><font style="FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif; FONT-WEIGHT: bold; DISPLAY: inline">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; LINE-HEIGHT: 12.55pt; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 12.55pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt" align="left">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 12.55pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt" align="left"><font style="FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">(b)&#160;&#160;On December 21, 2015, Acorda Therapeutics, Inc. (the &#8220;Company&#8221;) announced that Enrique Carrazana, M.D., the Company&#8217;s Chief Medical Officer (CMO) and one of its named executive officers, is leaving the Company effective January 4, 2016.&#160;&#160;Dr. Carrazana is expected to serve as a consultant to&#160;the Company for at least six (6) months following his departure.</font></div>

<div style="DISPLAY: block; LINE-HEIGHT: 13.7pt; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 12.55pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt" align="left"><font style="FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">The Company has engaged Burkhard Blank, M.D., to assume the responsibilities of CMO on an interim basis upon Dr. Carrazana&#8217;s departure. Dr. Blank has more than 25 years of industry experience, holding senior leadership positions with responsibility for managing international clinical trial programs, as well as heading regulatory affairs, statistics, drug safety and related departments. As CMO of Boehringer Ingelheim Pharmaceuticals, Inc., Dr. Blank oversaw the submission of five New Drug Applications (NDAs) and had direct responsibility for all aspects of presenting at two U.S. Food and Drug Administration (FDA) Advisory Committee Meetings;&#160;all five NDAs received FDA approval. Dr. Blank has also served as a strategic advisor to several biotechnology companies, leading the submission process for multiple Investigational Drug Applications (INDs), successfully developing protocols for clinical trial programs, and overseeing communications with regulatory agencies.&#160; Dr. Blank is a Board-certified internist and received his medical degree from Universitaet Marburg, Germany.</font></div>

<div style="DISPLAY: block; LINE-HEIGHT: 12.55pt; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 12.55pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt" align="left"><font style="FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">A copy of the press release announcing Dr. Carrazana&#8217;s departure and&#160;the Company's&#160;engagement of Dr. Blank on an interim basis is attached as Exhibit 99.1 to this Current Report on Form 8-K, and incorporated by reference into this Item.</font></div>

<div style="DISPLAY: block; LINE-HEIGHT: 12.55pt; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 12.55pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt" align="left"><font style="FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">(e)&#160;&#160;The Company intends to enter into a consulting agreement with Dr. Carrazana, effective as of his departure and subject to negotiation with Dr. Carrazana, pursuant to which he will provide certain consulting services to the Company during the consulting period in exchange for, among other things, the Company&#8217;s agreement to modify Dr. Carrazana&#8217;s outstanding stock options to extend vesting and exercise rights based on the consulting period.&#160;&#160;Dr. Carrazana will also receive compensation and benefits to which he is entitled pursuant to his existing employment agreement with the Company.</font></div>

<div style="DISPLAY: block; LINE-HEIGHT: 12.55pt; TEXT-INDENT: 0pt"><br>
</div>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 12.55pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt" align="left">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 12.55pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif; FONT-WEIGHT: bold; DISPLAY: inline">Item 9.01&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial Statements and Exhibits</font></div>

<div style="DISPLAY: block; LINE-HEIGHT: 12.55pt; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 12.55pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">(d) Exhibits</font></div>

<div style="DISPLAY: block; LINE-HEIGHT: 12.55pt; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="">
<tr>
<td align="left" valign="top" width="15%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 12.55pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 11pt; FONT-FAMILY: times new roman, serif; FONT-STYLE: italic; DISPLAY: inline"><font style="TEXT-DECORATION: underline; DISPLAY: inline">Exhibit No.</font></font></div>

<div style="DISPLAY: block; LINE-HEIGHT: 13.7pt; TEXT-INDENT: 0pt">&#160;</div>
</td>
<td align="left" valign="top" width="40%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 12.55pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 11pt; FONT-FAMILY: times new roman, serif; FONT-STYLE: italic; DISPLAY: inline"><font style="TEXT-DECORATION: underline; DISPLAY: inline">Description</font></font></div>

<div style="DISPLAY: block; LINE-HEIGHT: 13.7pt; TEXT-INDENT: 0pt">&#160;</div>
</td>
</tr><tr>
<td align="left" valign="top" width="15%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 12.55pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 11pt; FONT-FAMILY: times new roman, serif; DISPLAY: inline">99.1</font></div>
</td>
<td align="left" valign="top" width="40%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 12.55pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 11pt; FONT-FAMILY: times new roman, serif; DISPLAY: inline">Press Release dated December 21, 2015</font></div>
</td>
</tr></table>
</div>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>
</div>
</div>

<br>
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 12.55pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif; FONT-WEIGHT: bold; DISPLAY: inline">SIGNATURES</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 12.55pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">&#160;</font></div>

<div style="DISPLAY: block; LINE-HEIGHT: 12.55pt; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 12.55pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 12.55pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="">
<tr>
<td align="left" valign="top" width="40%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 12.55pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 11pt; FONT-FAMILY: times new roman, serif; DISPLAY: inline">&#160;</font></div>
</td>
<td align="left" colspan="2" valign="top" width="38%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 12.55pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 11pt; FONT-FAMILY: times new roman, serif; FONT-WEIGHT: bold; DISPLAY: inline">Acorda Therapeutics, Inc.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="40%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 12.55pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 11pt; FONT-FAMILY: times new roman, serif; DISPLAY: inline">&#160;</font></div>
</td>
<td align="left" valign="top" width="4%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 12.55pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 11pt; FONT-FAMILY: times new roman, serif; DISPLAY: inline">&#160;</font></div>
</td>
<td align="left" valign="top" width="35%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 12.55pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 11pt; FONT-FAMILY: times new roman, serif; DISPLAY: inline">&#160;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="40%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 12.55pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 11pt; FONT-FAMILY: times new roman, serif; DISPLAY: inline">December 21, 2015</font></div>
</td>
<td align="left" valign="top" width="4%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 12.55pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 11pt; FONT-FAMILY: times new roman, serif; DISPLAY: inline">By:</font></div>
</td>
<td align="left" valign="top" width="35%" style="BORDER-BOTTOM: black 1pt solid">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 12.55pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 11pt; FONT-FAMILY: times new roman, serif; DISPLAY: inline">/s/ Michael Rogers</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="40%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 12.55pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 11pt; FONT-FAMILY: times new roman, serif; DISPLAY: inline">&#160;</font></div>
</td>
<td align="left" valign="top" width="4%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 12.55pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 11pt; FONT-FAMILY: times new roman, serif; DISPLAY: inline">&#160;</font></div>
</td>
<td align="left" valign="top" width="35%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 12.55pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 11pt; FONT-FAMILY: times new roman, serif; DISPLAY: inline">Name: Michael Rogers</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="40%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 12.55pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 11pt; FONT-FAMILY: times new roman, serif; DISPLAY: inline">&#160;</font></div>
</td>
<td align="left" valign="top" width="4%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 12.55pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 11pt; FONT-FAMILY: times new roman, serif; DISPLAY: inline">&#160;</font></div>
</td>
<td align="left" valign="top" width="35%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 12.55pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 11pt; FONT-FAMILY: times new roman, serif; DISPLAY: inline">Title: Chief Financial Officer</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; LINE-HEIGHT: 13.7pt; TEXT-INDENT: 0pt"><br>
<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>
</div>
</div>

<br>
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 12.55pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif; FONT-WEIGHT: bold; DISPLAY: inline">EXHIBIT INDEX</font></div>

<div style="DISPLAY: block; LINE-HEIGHT: 12.55pt; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="">
<tr>
<td align="left" valign="top" width="19%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 12.55pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 11pt; FONT-FAMILY: times new roman, serif; FONT-STYLE: italic; DISPLAY: inline"><font style="TEXT-DECORATION: underline; DISPLAY: inline">Exhibit No.</font></font></div>

<div style="DISPLAY: block; LINE-HEIGHT: 13.7pt; TEXT-INDENT: 0pt">&#160;</div>
</td>
<td align="left" valign="top" width="40%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 12.55pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 11pt; FONT-FAMILY: times new roman, serif; FONT-STYLE: italic; DISPLAY: inline"><font style="TEXT-DECORATION: underline; DISPLAY: inline">Description</font></font></div>

<div style="DISPLAY: block; LINE-HEIGHT: 13.7pt; TEXT-INDENT: 0pt">&#160;</div>
</td>
</tr><tr>
<td align="left" valign="top" width="19%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 12.55pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 11pt; FONT-FAMILY: times new roman, serif; DISPLAY: inline">99.1</font></div>
</td>
<td align="left" valign="top" width="40%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 12.55pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 11pt; FONT-FAMILY: times new roman, serif; DISPLAY: inline">Press Release dated December 21, 2015</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; LINE-HEIGHT: 13.7pt; TEXT-INDENT: 0pt">&#160;</div>
</div>
</body>
</html>
[{"type": "8-K", "sequence": "1", "filename": "report_cmo-122115.htm", "description": "8-K", "secsgml_size_bytes": 32422}]
{"company-data": {"conformed-name": "ACORDA THERAPEUTICS INC", "cik": "0001008848", "assigned-sic": "2836", "irs-number": "000000000", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-50513", "film-number": "151298213"}, "business-address": {"street1": "420 SAW MILL RIVER ROAD", "city": "ARDSLEY", "state": "NY", "zip": "10502", "phone": "914-347-4300"}, "mail-address": {"street1": "420 SAW MILL RIVER ROAD", "city": "ARDSLEY", "state": "NY", "zip": "10502"}}
report_cmo-122115.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
December 21, 2015
Acorda Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Delaware
000-50513
13-3831168
(State or other jurisdiction
(Commission
(I.R.S. Employer
of incorporation)
File Number)
Identification No.)
420 Saw Mill River Road,
Ardsley, NY
10502
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including area code:
(914) 347-4300
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
(b)  On December 21, 2015, Acorda Therapeutics, Inc. (the "Company") announced that Enrique Carrazana, M.D., the Company's Chief Medical Officer (CMO) and one of its named executive officers, is leaving the Company effective January 4, 2016.  Dr. Carrazana is expected to serve as a consultant to the Company for at least six (6) months following his departure.
The Company has engaged Burkhard Blank, M.D., to assume the responsibilities of CMO on an interim basis upon Dr. Carrazana's departure. Dr. Blank has more than 25 years of industry experience, holding senior leadership positions with responsibility for managing international clinical trial programs, as well as heading regulatory affairs, statistics, drug safety and related departments. As CMO of Boehringer Ingelheim Pharmaceuticals, Inc., Dr. Blank oversaw the submission of five New Drug Applications (NDAs) and had direct responsibility for all aspects of presenting at two U.S. Food and Drug Administration (FDA) Advisory Committee Meetings; all five NDAs received FDA approval. Dr. Blank has also served as a strategic advisor to several biotechnology companies, leading the submission process for multiple Investigational Drug Applications (INDs), successfully developing protocols for clinical trial programs, and overseeing communications with regulatory agencies.  Dr. Blank is a Board-certified internist and received his medical degree from Universitaet Marburg, Germany.
A copy of the press release announcing Dr. Carrazana's departure and the Company's engagement of Dr. Blank on an interim basis is attached as Exhibit 99.1 to this Current Report on Form 8-K, and incorporated by reference into this Item.
(e)  The Company intends to enter into a consulting agreement with Dr. Carrazana, effective as of his departure and subject to negotiation with Dr. Carrazana, pursuant to which he will provide certain consulting services to the Company during the consulting period in exchange for, among other things, the Company's agreement to modify Dr. Carrazana's outstanding stock options to extend vesting and exercise rights based on the consulting period.  Dr. Carrazana will also receive compensation and benefits to which he is entitled pursuant to his existing employment agreement with the Company.
Item 9.01                      Financial Statements and Exhibits
(d) Exhibits
Exhibit No.
Description
99.1
Press Release dated December 21, 2015
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Acorda Therapeutics, Inc.
December 21, 2015
By:
/s/ Michael Rogers
Name: Michael Rogers
Title: Chief Financial Officer
EXHIBIT INDEX
Exhibit No.
Description
99.1
Press Release dated December 21, 2015